Matchpoint Therapeutics
Cambridge, US · Founded 2021 · 6 known investors
Find your way into Matchpoint Therapeutics
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
Founders & leadership
Board

Investors · 6
How we know: Access Biotechnology's portfolio page · funding news · Not right? Tell us
How we know: Digitalis Ventures's portfolio page · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$42M disclosed across 1 round · 2022
▶$42MraisedOct 2022 · 15 investors · PharmaceuticalsRule 506(b)
- Jason HaflerDirector
- Andre TurenneExecutive Officer, Director
- Bruce BoothDirector
- Daniel BeckerDirector
- Offering amount
- $70M
- Amount sold
- $42M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Matchpoint Therapeutics do?
- Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
- Who are Matchpoint Therapeutics's investors?
- Matchpoint Therapeutics's investors include Access Biotechnology, Digitalis Ventures, Sanofi Ventures, Access Industries, Alexandria, Atlas Venture.
- How much funding has Matchpoint Therapeutics raised?
- Matchpoint Therapeutics has disclosed $42M raised across 1 round.
- Where is Matchpoint Therapeutics headquartered?
- Matchpoint Therapeutics is headquartered in Cambridge, US.



